Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.63 |
| ▸ | ALPI | P09923 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | XIAP | P98170 | 1/20 | 0.63 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | LAP3 | P28838 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099705 | 1.00 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL73707 | 1.00 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL1168587 | 0.98 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL353729 | 0.98 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL6364440 | 0.98 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Carbamic Acid SCHEMBL13836019 | 0.96 | SLC7A5 (0.59) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL121369 | 0.93 | SLC7A5 (0.62) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL630209 | 0.93 | SLC7A5 (0.62) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL16080193 | 0.93 | SLC7A5 (0.62) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL26023571 | 0.93 | SLC7A5 (0.62) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 923 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | claimed |
| CN-118239879-A | Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine | 泰山学院 | 2024-06-25 | — | — | CN | claimed |
| CN-118007135-A | Corrosion inhibition method for inhibiting metal corrosion in sulfur-containing medium | 福建理工大学 | 2024-05-10 | — | — | CN | claimed |
| CN-112110987-B | 5-fluorouracil modified by asparaginyl theanine and phenylalanine, synthesis, activity and application thereof | 首都医科大学 | 2023-05-05 | — | — | CN | claimed |
| US-20220288358-A1 | Drug-Coated Balloon Controllable In Drug Metabolism And Preparation Method Therefor | SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED (CN) | 2022-09-15 | — | — | US | claimed |
| EP-4008390-A1 | DRUGCOATED BALLOON CONTROLLABLE IN DRUG METABOLISM AND PREPARATION METHOD THEREFOR | Shanghai Heartcare Medical Technology Corporation Limited (CN) | 2022-06-08 | — | — | EP | claimed |
| CN-114533890-A | Preparation method and product of sorafenib liver cancer targeting micelle | 平顶山学院 | 2022-05-27 | — | — | CN | claimed |
| CN-112010811-B | 5-fluorouracil modified by theanine and phenylalanine together, and synthesis, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | claimed |
| CN-106998771-B | Flavour composition and pet food comprising same | 马斯公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3351580-B1 | POLYMER CONJUGATE OF HEXA-COORDINATED PLATINUM COMPLEX | NIPPON KAYAKU KK (JP) | 2021-02-24 | — | — | EP | claimed |
| CN-1288155-C | Process for preparing optical active ketorolac | UNIV BEIJING (CN) | 2006-12-06 | — | — | CN | claimed |
| US-6897199-B2 | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-24 | — | — | US | claimed |
| EP-1363913-A2 | SALTS OF PYRIMIDINE DERIVATIVES FOR USE AGAINST CORONARY HEART DISEASE AND ATHEROSCLEROSE | Dr. Reddy's Laboratories Ltd. (IN) | 2003-11-26 | — | — | EP | claimed |
| CN-1434045-A | Process for preparing optical active ketorolac | UNIV BEIJING (CN) | 2003-08-06 | — | — | CN | claimed |
| US-20020169175-A1 | Pharmaceutically acceptable salts of heterocyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-11-14 | — | — | US | claimed |
| US-20020169146-A1 | Pharmaceutically acceptable salts of tricyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-11-14 | — | — | US | claimed |
| WO-2002062772-A1 | SALTS OF 3-4(4-(2-PHENOXAZIN- OR PHENOTHIAZIN-10-YL)ALKOXY)PHENYL)-2-ALKOXYPROPANOIC ACID DERIVATIVES WITH PPAR ACTIVITY FOR THE TREATMENT OF HYPERLIPIMEDIA AND TYPE II DIABETES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-08-15 | — | — | WO | claimed |
| WO-2002062798-A2 | SALTS OF PYRIMIDINE DERIVATIVES FOR USE AGAINST CORONARY HEART DISEASE AND ATHEROSCLEROSE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-08-15 | — | — | WO | claimed |
| US-5602161-A | ELASTASE INHIBITORS; PREVENTING AND TREATING EMPHYSEMA, ENDOTOXIN-INDUCED LUNG DISORDERS | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-11 | — | — | US | claimed |
| EP-0676396-A1 | Tetrazolylphenyl pivalate derivatives and medicinal composition containing the same as effective component | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1995-10-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169175-A1 | Pharmaceutically acceptable salts of heterocyclic compounds | CYP3A43, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | SLC7A5 308/4885ALPI 71/4885PKM 313/4885 |
| US-20020169146-A1 | Pharmaceutically acceptable salts of tricyclic compounds | CYP3A43, ABCG2, SLCO1B3 | SLC7A5 194/4885ALPI 81/4885PKM 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.